Daridorexant's Impact on Sleep in Chronic Insomnia

This study explores how well the medication daridorexant works for people with chronic insomnia, a condition that affects about 10% of the European population. Insomnia can lead to serious health issues like heart disease, depression, and diabetes. Daridorexant has been recommended in European guidelines as a first-choice treatment for insomnia because it avoids some side effects common with other sleep aids, such as feeling drowsy during the day or becoming dependent on the drug. By using a modern approach, this study aims to measure daridorexant's effectiveness in real-world settings compared to other treatments and identify which patients benefit the most from it. Participants in the study will take daridorexant 50 mg and their sleep quality will be monitored over three months. This will be done through self-reported questionnaires and a wearable device that tracks sleep patterns based on movement. The study will assess improvements in sleep quality, how long and efficiently people sleep, and how well they function during the day. By looking at these factors, researchers hope to understand how daridorexant helps with sleep and whether it can also alleviate symptoms of other sleep disorders. Potential risks are not highlighted, suggesting the focus is on evaluating positive outcomes and understanding the medication's effectiveness in real-life conditions.